Noelle Hanako Ebel, MD
Gastroenterology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ebel’s office at (650) 498-7200 to ask if they take your plan before you enroll.
California Medical Board record
Licence A123789 · Current
Licensed to practise in California · since 2012 · expires 2028-12-31 · Boston University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$776 in 2024
Medicaid paid $776 for 13 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 13 | $776 |
| 2024 | 13 | 1 | 12 | $776 |
| 2023 | 90 | 2 | 15 | $9,697 |
| 2022 | 185 | 2 | 26 | $19,275 |
| 2021 | 277 | 2 | 25 | $32,819 |
| 2020 | 25 | 1 | 18 | $3,197 |
| 2019 | 12 | 1 | 12 | $1,398 |
| 2018 | 68 | 3 | 23 | $5,871 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 59 | $7,746 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 31 | $1,951 |
2022
| Long return visit (40+ min) | 122 | $15,608 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 63 | $3,667 |
2021
| Long return visit (40+ min) | 231 | $28,806 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 46 | $4,014 |
2020
| OFF/OP CNSLTJ NEW/EST MOD 40 | 25 | $3,197 |
2019
| Long return visit (40+ min) | 12 | $1,398 |
2018
| New patient visit (45+ min) | 35 | $3,059 |
| New patient visit (30+ min) | 21 | $1,606 |
| Long return visit (40+ min) | 12 | $1,206 |
Money from drug and device companies
$31,033 in 2025
| 2025 | 2 | 24 | $27,514 | $31,033 |
| 2024 | 2 | 19 | $23,617 | $25,065 |
| 2023 | 3 | 20 | $33,904 | $36,752 |
| 2022 | 1 | 7 | $17,950 | $17,950 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mirum Pharmaceuticals | Livmarli | $20,608 | 20 payments
|
| Ipsen Biopharmaceuticals | Bylvay | $10,425 | 4 payments
|
See all 24 published payments
| Mirum Pharmaceuticals | Meals · 2025-04-23 | Livmarli | $29 |
| Mirum Pharmaceuticals | Meals · 2025-04-23 | Livmarli | $127 |
| Mirum Pharmaceuticals | Consulting · 2025-04-23 | Livmarli | $3,080 |
| Mirum Pharmaceuticals | Consulting · 2025-04-23 | Livmarli | $5,250 |
| Mirum Pharmaceuticals | Travel · 2025-04-23 | Livmarli | $249 |
| Mirum Pharmaceuticals | Travel · 2025-04-23 | Livmarli | $182 |
| Mirum Pharmaceuticals | Meals · 2025-04-05 | Livmarli | $25 |
| Mirum Pharmaceuticals | Meals · 2025-04-05 | Livmarli | $46 |
| Mirum Pharmaceuticals | Consulting · 2025-04-04 | Livmarli | $5,200 |
| Mirum Pharmaceuticals | Travel · 2025-04-04 | Livmarli | $90 |
| Mirum Pharmaceuticals | Meals · 2025-04-04 | Livmarli | $50 |
| Mirum Pharmaceuticals | Travel · 2025-04-04 | Livmarli | $46 |
| Mirum Pharmaceuticals | Meals · 2025-04-04 | Livmarli | $32 |
| Mirum Pharmaceuticals | Travel · 2025-04-04 | Livmarli | $64 |
| Mirum Pharmaceuticals | Travel · 2025-04-04 | Livmarli | $30 |
| Mirum Pharmaceuticals | Consulting · 2025-04-04 | Livmarli | $3,494 |
| Mirum Pharmaceuticals | Meals · 2025-04-04 | Livmarli | $149 |
| Mirum Pharmaceuticals | Travel · 2025-04-04 | Livmarli | $413 |
| Mirum Pharmaceuticals | Travel · 2025-04-04 | Livmarli | $512 |
| Mirum Pharmaceuticals | Consulting · 2025-03-12 | Livmarli | $1,540 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-01-01 | Bylvay | $8,951 |
| Ipsen Biopharmaceuticals | Travel · 2025-01-01 | Bylvay | $299 |
| Ipsen Biopharmaceuticals | Travel · 2025-01-01 | Bylvay | $1,045 |
| Ipsen Biopharmaceuticals | Meals · 2025-01-01 | Bylvay | $130 |
See earlier years (2024, 2023, 2022)
2024: $25,065
| Mirum Pharmaceuticals | Livmarli | $15,271 | 15 payments
|
| Ipsen Biopharmaceuticals | Bylvay | $9,794 | 4 payments
|
2023: $36,752
| Ipsen Biopharmaceuticals | Bylvay | $21,700 | 11 payments
|
| Mirum Pharmaceuticals | Livmarli | $13,257 | 8 payments
|
| Albireo Pharma | Bylvay | $1,795 | 1 payment
|
2022: $17,950
| Mirum Pharmaceuticals | Livmarli | $17,950 | 7 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Mirum Pharmaceuticals, Inc. · Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (Expand) · 2025 | Their institution | $23,306 |
| Mirum Pharmaceuticals, Inc. · A Study To Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (Pfic) and Alagille Syndrome (Algs) (Rise) · 2023 | Their institution | $1,280 |
Professional record
- NPI
- 1376834697
- Licence
- CA A123789California A123789: Current · expires 2028-12-31
- Trained
- Boston University School of Medicine, 2011
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080T0004X (2080T0004X); Federal specialty code 2080P0206X (2080P0206X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2011-04-20
- NPI last updated
- 2024-04-10
- NPI record certified
- 2024-04-10
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 750 Welch Rd Ste 116, Palo Alto, CA, 94304